Dr. Le on Next Steps With Poziotinib in EGFR+ or HER2+ Exon 20 NSCLC

Xiuning Le, MD, PhD

Xiuning Le, MD, PhD, discusses next steps with poziotinib (NOV120101, HM781-36B) in patients with EGFR-positive or HER2-positive exon 20–mutant non–small cell lung cancer.

Xiuning Le, MD, PhD, an assistant professor of thoracic/head and neck medical oncology, Division of Internal Medicine, at The University of Texas MD Anderson Cancer Center, discusses next steps with poziotinib (NOV120101, HM781-36B) in patients with EGFR- or HER2-positive exon 20–mutant non–small cell lung cancer (NSCLC).

The agent was examined in the phase 2 ZENITH20 trial (NCT03318939), which administered poziotinib twice daily in patients with EGFR- or HER2-positive exon 20–mutant NSCLC, according to Le. This trial had numerous arms, with cohort 2 focused on patients with HER2-positive exon 20 disease who had received prior therapies. Patients in this cohort experienced an objective response rate of 27.8%.

The next steps for poziotinib involve going through the FDA fast-track process, Le says. By optimizing the treatment regimen, it is possible to provide patients with a better quality of life, as well as keep them on the drug longer, which may potentially improve efficacy. Through this, it is possible that more patients, including those who are EGFR positive, may benefit from treatment with poziotinib, Le concludes.